These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4005813)

  • 1. Glycosaminoglycans in malignant diffuse mesothelioma.
    Kawai T; Suzuki M; Shinmei M; Maenaka Y; Kageyama K
    Cancer; 1985 Aug; 56(3):567-74. PubMed ID: 4005813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosaminoglycans of pleural mesothelioma: a possible biochemical variant containing chondroitin sulfate.
    Iozzo RV; Goldes JA; Chen WJ; Wight TN
    Cancer; 1981 Jul; 48(1):89-97. PubMed ID: 6786728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycosaminoglycan in malignant pleural mesothelioma.
    Nakano T; Fujii J; Tamura S; Amuro Y; Nabeshima K; Horai T; Hada T; Higashino K
    Cancer; 1986 Jan; 57(1):106-10. PubMed ID: 3940610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case reports of primary pulmonary adenocarcinoma with pleural spread: so-called pseudomesotheliomatous adenocarcinoma.
    Saito R; Kasajima A; Taniuchi S; Fujishima F; Ishida K; Nakamura Y; Yamanda S; Takahashi T; Hitomi H; Murakami K; Watanabe M; Sasano H
    Pathol Int; 2012 Oct; 62(10):709-15. PubMed ID: 23005599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical comparison of diffuse malignant mesothelioma of the pleura and pseudomesotheliomatous carcinoma of the lung for each case].
    Yuasa H; Tomoyasu M
    Kyobu Geka; 1999 Sep; 52(10):836-9. PubMed ID: 10478545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
    Galloway ML; Murray D; Moffat DF
    Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
    [No Abstract]   [Full Text] [Related]  

  • 7. Synchronous occurrence of pulmonary adenocarcinoma and pleural diffuse malignant mesothelioma.
    Imenpour H; Ivaldi GP; Brianti A; Pastorino G; Biggi S; Auriati L; Simonassi C
    Pathologica; 2013 Dec; 105(6):353-6. PubMed ID: 24730341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.
    Kao SC; Griggs K; Lee K; Armstrong N; Clarke S; Vardy J; van Zandwijk N; Burn J; McCaughan BC; Henderson DW; Klebe S
    Pathology; 2011 Jun; 43(4):313-7. PubMed ID: 21532523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study on acid glycosaminoglycans in pleural diseases.
    Arai H
    Sci Rep Res Inst Tohoku Univ Med; 1979 Dec; 26(3-4):46-70. PubMed ID: 547421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant mesothelioma masquerading as a multinodular bronchioloalveolar cell adenocarcinoma with widespread pulmonary nodules.
    Felner KJ; Wieczorek R; Kline M; Smith RL; Sidhu GS
    Int J Surg Pathol; 2006 Jul; 14(3):229-33. PubMed ID: 16959710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pleural mesothelioma: morphology, histochemistry, difficulties in diagnosis and nosologic problems (author's transl)].
    Abelanet R; Jagueux M; Fondimare A; Roujeau J
    Rev Fr Mal Respir; 1979; 7(3):243-64. PubMed ID: 91185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Pseudomesotheliomatous' carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff.
    Attanoos RL; Gibbs AR
    Histopathology; 2003 Nov; 43(5):444-52. PubMed ID: 14636270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleural mesothelioma in situ and its adenocarcinoma simulator.
    Bono F
    Int J Surg Pathol; 2010 Dec; 18(6):519-20. PubMed ID: 21081535
    [No Abstract]   [Full Text] [Related]  

  • 16. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H; Kibar Y; Güldür ME; Bakir K
    Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.
    Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C
    Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
    Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
    Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-cadherin in mesothelioma.
    Jeffers M
    Hum Pathol; 1996 Nov; 27(11):1245-6. PubMed ID: 8912839
    [No Abstract]   [Full Text] [Related]  

  • 20. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.
    Di Loreto C; Puglisi F; Di Lauro V; Damante G; Beltrami CA
    Cancer Lett; 1998 Feb; 124(1):73-8. PubMed ID: 9500194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.